Autopsy report · NCT00884039

Anecortave Acetate Injection to Treat Steroid-responsive Intraocular Pressure Increase in Cornea Transplant Patients

“Preliminary data analysis showed insufficient efficacy to justify continuation.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 4 months before it stopped.
• 7 participants enrolled.
• Results were posted on the registry 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Cornea Research Foundation of America

Sponsor type

University, hospital or other

Conditions

Transplant; Intraocular Pressure

Interventions

anecortave acetate; 30 mg anecortave acetate

Participants

7

Sites

1

Countries

United States

Trials that died the same way

• BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis
  “Results from pre-specified criteria did not demonstrate sufficient efficacy to warrant continuation of the study.” (77% match in meaning)
• A Study of LY3405105 in Participants With Advanced Cancer
  “The study was terminated for lack of sufficient efficacy.” (73% match in meaning)
• LBH589 in Refractory Myelodysplastic Syndromes (MDS)
  “Per protocol, the results of a planned interim analysis demonstrated insufficient efficacy and led to early termination of the study.” (72% match in meaning)
• A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia
  “Study termination due to insufficient efficacy.” (72% match in meaning)
• Cross Linking for Treatment of Corneal Infection
  “insufficient efficacy” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.